Small Preliminary Trial of Psychoactive Drug Ibogaine Yields ‘Initial Evidence’ for Powerful Therapeutic Potential in Traumatic Brain Injury

January 25, 2024

In an exploratory and preliminary clinical test, a team of researchers at Stanford University has obtained “initial evidence” suggesting that a psychoactive compound called ibogaine, when co-administered with magnesium, “could be a powerful therapeutic” to safely treat a variety of psychiatric symptoms, including PTSD, major depression and anxiety, and suicidality, all of which may emerge following traumatic brain injury (TBI).

Ibogaine, derived from the root bark of a shrub, has been used for traditional religious and healing purposes in Africa for centuries. Sometimes called an atypical psychedelic, the Stanford researchers prefer to classify it as an “oneirogen,” based on a Greek word that describes its main psychotropic effect: therapeutic dosing leads to dreamlike states of consciousness that persist for several hours and sometimes even longer. Proponents of the compound say it facilitates self-reflection and self-evaluation. These are qualities that in recent years have been attributed to psychedelic compounds such as MDMA, psilocybin, and LSD. Like those agents, ibogaine since 1970 has been listed by the U.S. Drug Enforcement Administration as a Schedule I compound, with no officially recognized medical use and with a “high potential for misuse.”

Read the full article at The Brain & Behavior Research Foundation »

Comments are closed.